Nurix Therapeutics (NRIX) Receivables (2020 - 2025)

Nurix Therapeutics (NRIX) has 6 years of Receivables data on file, last reported at $6.5 million in Q4 2025.

• On a quarterly basis, Receivables changed 0.0% year-over-year to $6.5 million in Q4 2025; TTM through Nov 2025 was $6.5 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $6.5 million, changed 0.0% from the prior year.
• Receivables for Q4 2025 stood at $6.5 million, down from $20.7 million in the prior quarter.
• Over the last five years, Receivables for NRIX reached as high as $20.7 million in Q2 2025 and fell as low as $2.1 million in Q4 2022.
• Historically, Receivables has averaged $6.2 million across 5 years, with a median of $6.2 million in 2023.
• Across the five-year window, Receivables tumbled 69.57% in 2022 and jumped 225.0% in 2025, its largest moves.
• Year by year, Receivables stood at $6.9 million in 2021, then tumbled by 69.57% to $2.1 million in 2022, then surged by 128.57% to $4.8 million in 2023, then jumped by 35.42% to $6.5 million in 2024, then changed by 0.0% to $6.5 million in 2025.
• Per Business Quant data, the three most recent Receivables figures were $6.5 million in Q4 2025, $20.7 million in Q2 2025, and $9.1 million in Q1 2025.